| Greg L Sanders, CRNA | |
|
150 S 100 W, Oak City, UT 84649-0045 | |
| (435) 406-6641 | |
| Not Available |
| Full Name | Greg L Sanders |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 150 S 100 W, Oak City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013156561 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 5680456-4406 (Utah) | Primary |
| Entity Name | Amsurg St George Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730452814 PECOS PAC ID: 0749442523 Enrollment ID: O20120425000140 |
News Archive
Professional drivers working in congested cities are exposed to black carbon levels that are on average a third higher than would be experienced at a busy roadside, according to research presented at the European Respiratory Society International Congress.
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.
With viruses such as Ebola, MERS-CoV and Zika making global headlines, and the progressive development of antimicrobial resistance (AMR) worldwide, Edinburgh Research & Innovation (ERI), the commercialisation arm of the University of Edinburgh, has announced a new AIMday (Academic Industry Meeting day) for companies looking to find expertise and innovative solutions to dealing with the challenges of microbial infection.
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.
Custom Spine, a company dedicated to offering advanced spinal solutions, launched two new innovative spine systems at the North American Spine Society's (NASS) annual meeting being held in San Francisco.
› Verified 4 days ago
| Entity Name | Innovative Anesthesia Solutions Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730766098 PECOS PAC ID: 2062817760 Enrollment ID: O20210818002306 |
News Archive
Professional drivers working in congested cities are exposed to black carbon levels that are on average a third higher than would be experienced at a busy roadside, according to research presented at the European Respiratory Society International Congress.
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.
With viruses such as Ebola, MERS-CoV and Zika making global headlines, and the progressive development of antimicrobial resistance (AMR) worldwide, Edinburgh Research & Innovation (ERI), the commercialisation arm of the University of Edinburgh, has announced a new AIMday (Academic Industry Meeting day) for companies looking to find expertise and innovative solutions to dealing with the challenges of microbial infection.
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.
Custom Spine, a company dedicated to offering advanced spinal solutions, launched two new innovative spine systems at the North American Spine Society's (NASS) annual meeting being held in San Francisco.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Greg L Sanders, CRNA Po Box 54, Oak City, UT 84649-0045 Ph: (435) 406-6641 | Greg L Sanders, CRNA 150 S 100 W, Oak City, UT 84649-0045 Ph: (435) 406-6641 |
News Archive
Professional drivers working in congested cities are exposed to black carbon levels that are on average a third higher than would be experienced at a busy roadside, according to research presented at the European Respiratory Society International Congress.
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.
With viruses such as Ebola, MERS-CoV and Zika making global headlines, and the progressive development of antimicrobial resistance (AMR) worldwide, Edinburgh Research & Innovation (ERI), the commercialisation arm of the University of Edinburgh, has announced a new AIMday (Academic Industry Meeting day) for companies looking to find expertise and innovative solutions to dealing with the challenges of microbial infection.
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.
Custom Spine, a company dedicated to offering advanced spinal solutions, launched two new innovative spine systems at the North American Spine Society's (NASS) annual meeting being held in San Francisco.
› Verified 4 days ago